Sermorelin (5mg)

Sermorelin Peptide Mechanisms and Applications

The properties of Sermorelin, a 29-amino acid peptide, distinguish it as the shortest synthetically developed peptide with the capacity to elicit biological responses. Serving as an exact counterpart to growth hormone-releasing hormone (GHRH), the polypeptide adopts an analog structure, GHRH (1-29 acid)-amide. This distinctive configuration has spurred extensive exploration in diverse scientific domains, particularly within the realm of growth hormone deficiency, unveiling various mechanisms and potential applications.

In the early 1980s, researchers delved into the effects of growth hormone fragment GHRF (1-29) amide. Numerous studies were conducted on rat models, introducing exogenous GHRF (1-29) amide in both conscious and anesthetized rats. The results indicated that the presence of GHRF seemed to activate the pituitary gland, fostering growth in the subjects. This discovery propelled the exploration of growth hormone secretagogues, such as Sermorelin, as promising compounds to advance investigations into growth hormone deficiencies.

Overview

Sermorelin, a growth hormone analogue, comprises the initial 29 amino acids of the typical 44 amino acids in growth hormone (HGH). Scientific studies propose that Sermorelin has an affinity for binding with growth hormone receptors located on the pituitary gland, leading researchers to speculate that this synthetic peptide has the potential to initiate the secretion of growth hormones.

The primary capability of the peptide lies in its purported ability to avoid substantial alterations in prolactin, insulin, cortisol, glucose, or thyroid hormone levels – as elaborated in the subsequent research investigations below. Regarded as a growth hormone analogue, the peptide is believed to share many potential actions with the naturally existing growth hormone.

Scientific Investigations and Clinical Analyses

Sermorelin Peptide and Pediatric Growth Disorders

In the examination of pediatric growth disorders characterized by idiopathic growth hormone deficiency, the introduction of Sermorelin to young subjects demonstrated notable outcomes. Over a 12-month period of consistent administration, researchers documented a significant enhancement in growth rate and height velocity. Impressively, these heightened growth levels were noted to persist for an average duration of 36 months following continuous exposure to the peptide.

Sermorelin Peptide and HIV-Associated Lipodystrophy

In a rigorously controlled clinical investigation involving 31 individuals with HIV and lipodystrophy, researchers delved into the potential effects of Sermorelin.(8) The participants were divided into two groups, with one receiving Sermorelin and the other a placebo over a 12-week period. The findings suggested a substantial increase in growth hormone levels among those administered with Sermorelin in comparison to the placebo group. Additionally, levels of insulin-like growth factor (IGF-1) were noted to rise, contributing to augmented lean body mass in subjects treated with the peptide. Remarkably, the Sermorelin group displayed a significant reduction in abdominal visceral fat and the ratio of trunk to lower extremity fat. Notably, no discernible changes were reported in glucose or insulin levels.⁽⁸⁾

Sermorelin Peptide and Aging-Related Cognitive Decline

In the early 2000s, comprehensive clinical investigations involved 89 elderly participants aged between 68 and 69 years. The primary objective was to examine potential links between declining growth hormone release and cognitive impairment, often associated with the natural aging process. Researchers postulate that as individuals age, the diminishing levels of growth hormone may contribute to a decline in various physiological functions, including cognitive abilities. Upon the administration of Sermorelin, noticeable improvements were observed in the Wechsler Adult Intelligence Scale (WAIS), indicating enhanced IQ levels, performance on picture arrangement tests, and verbal assessments among the study participants.⁽⁹⁾

Sermorelin Peptide and Cancer Cell Sensitivity

In an extensive clinical investigation, 1,018 individuals with gliomas were exposed to more than 4,000 compounds, with each presentation followed by the determination of a Drug Response Score (DRS) for all compounds in each subject. Notably, the results of the study indicated that Sermorelin exhibited the highest reported sensitivity among the test subjects. Upon thorough analysis, researchers suggested that this heightened sensitivity may be attributed to the potential of Sermorelin to interfere with tumor cell cycles, potentially impeding the proliferation of cancerous cells.(10)

Sermorelin Peptide and Metabolic Impact

Early investigations into Sermorelin suggested potential effects on increasing lean mass in experimental subjects. A study aimed to assess the metabolic impact of Sermorelin, particularly in the context of hypogonadism associated with excess fat mass. The test subjects were divided into two groups, with one group receiving Sermorelin followed by GHRH 1-40, and the other group receiving the same combination in reverse order, with a one-week interval between the two compounds. Results from the study indicated that Sermorelin, in both groups, appeared to stimulate the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), potentially influencing testosterone production.

The preliminary investigations led to further studies, including a clinical trial involving 19 male participants, with 9 individuals aged between 22 and 33 years and 10 aged between 60 and 78 years. The older participants received one of two concentrations of Sermorelin over a 28-day period, with a 14-day interval between the two administrations. While the testosterone levels in the older subjects reportedly increased after Sermorelin administration, the changes were not deemed statistically significant. Additionally, researchers suggested that heightened growth hormone levels, potentially triggered by the presence of Sermorelin, were observed to peak during nighttime for all participants, in contrast to daytime levels.⁽¹¹⁾
Sermorelin peptide is exclusively intended for research and laboratory use. Prior to placing an order, it is essential to review and comply with our specified Terms and Conditions.